In a report released today, Michael Petusky from Barrington maintained a Buy rating on Landec (LNDC – Research Report), with a price target of $14.00. The company’s shares opened today at $9.92.
Petusky covers the Healthcare sector, focusing on stocks such as Lemaitre Vascular, Haemonetics, and Merit Medical Systems. According to TipRanks, Petusky has an average return of 7.6% and a 49.85% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Landec with a $13.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
LNDC market cap is currently $291.6M and has a P/E ratio of -3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landec Corp. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Curation Foods, Lifecore, and Others. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Clara, CA.
Read More on LNDC:
